Targeted anti-cancer drugs, which bind and inhibit specific components of aberrant signaling pathways, are a promising alternative to conventional chemotherapy, with recent successes in melanoma (RAF inhibitor) [2] and prostate cancer (AR inhibitor) [3], [4] following in the footsteps of the pioneering BCR-ABL inhibitor Imatinib [5] and EGFR inhibitors Gefitinib and Erlotinib [6], [7], [8]. The gene discussed is EGFR; the disease is melanoma.